
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Maintaining minimum standards can compromise the quality of your data and the rights and safety of study subjects.
over 25 years ago
Public Key Infrastructure: The Beginning of a Beautiful Friendship?over 25 years ago
Ethics, Kids, and Sexover 25 years ago
Clinical Research Training on the Webover 25 years ago
The EMEA Keeps Up-to-Dateover 25 years ago
The Virtual Organization: Is It the Future Industry Landscape?over 25 years ago
Letters to the Editorover 25 years ago
David Sabrittover 25 years ago
The Virtual Organizationover 25 years ago
Guest Editorial





